ET8 Stock Overview
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aeterna Zentaris Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.80 |
| 52 Week High | CA$2.88 |
| 52 Week Low | CA$1.27 |
| Beta | 2.07 |
| 1 Month Change | -6.83% |
| 3 Month Change | 4.05% |
| 1 Year Change | -33.33% |
| 3 Year Change | -90.15% |
| 5 Year Change | -98.05% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| ET8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -4.3% | -2.5% |
| 1Y | -33.3% | -19.4% | -0.4% |
Return vs Industry: ET8 underperformed the German Biotechs industry which returned -15.8% over the past year.
Return vs Market: ET8 underperformed the German Market which returned 1% over the past year.
Price Volatility
| ET8 volatility | |
|---|---|
| ET8 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ET8 has not had significant price volatility in the past 3 months.
Volatility Over Time: ET8's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Klaus Paulini | www.zentaris.com |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
Aeterna Zentaris Inc. Fundamentals Summary
| ET8 fundamental statistics | |
|---|---|
| Market cap | €8.92m |
| Earnings (TTM) | -€15.51m |
| Revenue (TTM) | €4.22m |
2.2x
P/S Ratio-0.6x
P/E RatioIs ET8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ET8 income statement (TTM) | |
|---|---|
| Revenue | US$4.50m |
| Cost of Revenue | US$222.00k |
| Gross Profit | US$4.28m |
| Other Expenses | US$20.83m |
| Earnings | -US$16.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.41 |
| Gross Margin | 95.06% |
| Net Profit Margin | -367.99% |
| Debt/Equity Ratio | 0% |
How did ET8 perform over the long term?
See historical performance and comparison